This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 14 - 17, 2025
Marriott Marquis San DiegoLive In-Person Event: December 14 - 17, 2025
BOOK NOW
Menu
BOOK NOW
keyboard_arrow_right

Pre-Conference Workshops (pm only) and Training Course (full day) - PT (Pacific Time, GMT-08:00)

keyboard_arrow_leftSearch & Filter
search
Pre-Conference Workshops (pm only) and Training Course (full day) - PT (Pacific Time, GMT-08:00)
search
Optional Pre-Conference Training Course (9:00am-5:00pm) and Pre-Conference Workshops (1:00pm-5:00pm)
Showing 1 of 1 Streams
1:00pm - 1:15pm
Co-Chairs' Remarks: Innovate, Invest, Succeed: The Business Landscape of Antibody Therapeutics
  • Jonathan Sockolosky, PhD - Senior Director, CSO Partner Team, Curie.Bio
  • Jennifer Cochran, Ph.D. - Professor and Department Chair of Bioengineering, Stanford University
1:15pm - 1:45pm
Creating Value in Biotech: Insights from an Investor Turned Operator and Back Again

This session will offer perspective on what it takes to create value for biotechnology companies with a focus on early-stage (seed and Series A) therapeutics companies.

  • Kelly Moynihan, PhD - VP, CSO Partner Team, Curie.Bio
1:45pm - 2:15pm
Lessons Learned during the Transition from Preclinical to Early Clinical Development/Clinical POC
  • Mohit Trikha, PhD - President & COO, Kivu Biosciences
2:15pm - 2:45pm
Mixing and Matching: Partnering vs. Internal Development of Novel Antibodies

New antibody therapies span a wide range of indications with varying development costs and complexity. Partnering programs validates technology platforms, brings resources to bear, and raises funds, but dilutes ownership and long-term value. Novel antibody case studies from a range of program development stages and company sizes will be critically discussed.

  • Bassil Dahiyat, PhD - President and CEO, Xencor
2:45pm - 3:15pm
Networking Refreshment Break
3:15pm - 3:45pm
Speaker TBA
3:45pm - 4:15pm
Speaker TBA
4:15pm - 4:45pm
Panel Discussion
  • Jonathan Sockolosky, PhD - Senior Director, CSO Partner Team, Curie.Bio
  • Jennifer Cochran, Ph.D. - Professor and Department Chair of Bioengineering, Stanford University
4:45pm - 5:00pm
Concluding Remarks
NextMain Conference Day 1
Filter
Streams
Clear
Formats
Choose Day